{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06430684",
            "orgStudyIdInfo": {
                "id": "SGLT2I-IN-KIDS"
            },
            "secondaryIdInfos": [
                {
                    "id": "K23DK138313",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/K23DK138313"
                }
            ],
            "organization": {
                "fullName": "Ann & Robert H Lurie Children's Hospital of Chicago",
                "class": "OTHER"
            },
            "briefTitle": "Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease",
            "officialTitle": "Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease",
            "acronym": "SGLT2I-IN-KIDS",
            "therapeuticArea": [
                "Nephrology and Renal Diseases"
            ],
            "study": "feasibility-trial-of-sodium-glucose-cotransporter-inhibitors-in-pediatric-chronic-kidney-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-16",
            "studyFirstSubmitQcDate": "2024-05-21",
            "studyFirstPostDateStruct": {
                "date": "2024-05-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Alexander Kula",
                "investigatorTitle": "Assistant Professor of Pediatrics (Nephrology)",
                "investigatorAffiliation": "Ann & Robert H Lurie Children's Hospital of Chicago"
            },
            "leadSponsor": {
                "name": "Ann & Robert H Lurie Children's Hospital of Chicago",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are:\n\n1. Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)?\n2. Does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests?\n\nParticipants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care.\n\nStudy Procedures Include\n\n* For participants randomly selected for treatment, take empagliflozin once daily for 3 months\n* Phone calls with researchers every 2 weeks for check-ins\n* For participants taking empagliflozin, clinic visits 4 and 8 weeks after starting for check-ups and tests\n* All study participants will have clinic visits at the beginning and end (3 months) where researchers will collect information about their health and perform tests"
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Kidney Diseases",
                "Pediatric Kidney Disease"
            ],
            "keywords": [
                "Sodium Glucose Co-Transporter 2 Inhibitor",
                "SGLT2i",
                "Pediatric CKD",
                "Feasibility Study",
                "Clinical Trial"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Empagliflozin 10mg daily for 3 months (n=20)",
                    "interventionNames": [
                        "Drug: Empagliflozin 10 MG"
                    ]
                },
                {
                    "label": "Standard of Care",
                    "type": "NO_INTERVENTION",
                    "description": "Participants will not take empagliflozin (n=20)"
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Empagliflozin 10 MG",
                    "description": "Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older",
                    "armGroupLabels": [
                        "Treatment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of participants who complete all study procedures",
                    "description": "Compared to the number recruited, how many participants complete the study",
                    "timeFrame": "4 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Systolic Blood Pressure",
                    "description": "In-clinic systolic blood pressure",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Serum N-terminal pro-brain natruetic peptide (NT-proBNP)",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Urine Albumin to Creatinine Ratio (UACr)",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Left Atrial Reservoir Strain",
                    "description": "Measuring using echocardiography",
                    "timeFrame": "3 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage 3-4 CKD; estimated GFR using CKiD U25-creatinine equation 20-60mL/min/1.73m2\n\nExclusion Criteria:\n\n* Heart Disease\n* Diabetes\n* Pregnancy\n* Recipient of solid organ transplant\n* history of chemotherapy or stem cell transplant\n* moderate to severe persistent asthma\n* liver disease\n* class 2 or greater obesity\n* inability to follow study procedures due to cognitive impairment\n* obstructive uropathy or requirement for intermittent urinary catheterization\n* systolic blood pressure \\<100mgHg\n* orthostatic hypotension\n* current use of an SGLT2i\n* anticipated need for titration of anti-hypertensives within 3 months\n* active use of any immunosuppressive medications\n* lack of clearance by primary nephrologist for participation",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "maximumAge": "25 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alexander J Kula, MD, MHS",
                    "role": "CONTACT",
                    "phone": "312-227-6160",
                    "email": "alexkula@luriechildrens.org"
                }
            ],
            "locations": [
                {
                    "facility": "Ann & Robert H. Lurie Children's Hospital of Chicago",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander J Kula, MD, MHS",
                            "role": "CONTACT",
                            "phone": "312-227-6160",
                            "email": "alexkula@luriechildrens.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000051436",
                    "term": "Renal Insufficiency, Chronic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "asFound": "Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26717",
                    "name": "Renal Insufficiency, Chronic",
                    "asFound": "Chronic Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000570240",
                    "term": "Empagliflozin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000077203",
                    "term": "Sodium-Glucose Transporter 2 Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1691",
                    "name": "Sodium-Glucose Transporter 2 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M258082",
                    "name": "Empagliflozin",
                    "asFound": "Continued",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}